1ST Biotherapeutics, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.1stbio.com
Clinical Trials
4
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT07126704
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Phase 1
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease Psychosis
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05995782
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Phase Ib dose-expansion of FB849 monotherapyDrug: Phase Ia dose-escalation part of FB849 Monotherapy
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT05761223
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04165837
- Locations
- 🇺🇸
PAREXEL, Baltimore, Maryland, United States
News
No news found